A clear majority of patients with cancer experience some sort of financial hardship, and the cost of care is something that weighs on the minds of patients and their families right from the moment of diagnosis, said Todd Yezefski, MD, senior fellow in the Clinical Research Division at the Fred Hutchinson Cancer Research Center and Division of Medical Oncology at the University of Washington.
A clear majority of patients with cancer experience some sort of financial hardship, and the cost of care is something that weighs on the minds of patients and their families right from the moment of diagnosis, said Todd Yezefski, MD, senior fellow in the Clinical Research Division at the Fred Hutchinson Cancer Research Center and Division of Medical Oncology at the University of Washington.
Transcript
At what point after a cancer diagnosis do patients and families start to think about the financial costs?
I think really from that initial diagnosis, patients are thinking about the cost of their care. It’s something that’s weighing on their minds. From the first appointment, they’re getting bills from the hospital, the doctors, they need to pay copays and coinsurance. I think that the financial assistance and financial navigation should start right from the beginning because that’s when patients start to notice the costs and it only keeps growing from there.
How does experiencing financial hardships impact the outcomes of a patient’s care?
Studies have shown that up to 75% of patients experience some sort of financial hardship as a result of their cancer diagnosis and treatment. Patients often times have to stop working if they are already working, spouses and partners sometimes need to stop work. Patients who have a diagnosis of cancer have a higher rate of bankruptcy than people who don’t. So, the financial hardships are real and people experience them and they can be really distressing and troubling.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Phase 1 Study Identifies Casdatifan Dose With Promising Responses in Pretreated Clear Cell RCC
February 18th 2025Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell carcinoma (RCC).
Read More